| Document |
Document Title |
|
WO/2021/024925A1 |
The present invention aims to provide: a chemically amplified positive photosensitive resin composition that contains an acid generator having excellent solvent solubility and can readily form a resist pattern having excellent mask linea...
|
|
WO/2020/234636A1 |
Present invention relates to the novel heterocyclic compounds of the general formula (I) their tautomeric forms, their stereoisomers and their pharmaceutically acceptable salts etc. The invention also relates to pharmaceutical compositio...
|
|
WO/2020/135872A1 |
Provided are a drug, a pharmaceutical composition, or a pharmaceutical kit for immunosuppression, for the treatment of conditions such as psoriasis, comprising a forskolin derivative or a salt thereof and optionally a prostaglandin compo...
|
|
WO/2020/106028A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/103864A1 |
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L1, L2, L3, Ⓐ, Ⓑ, Ⓒ are as defined as set forth in the specification. Disclosed is compound of formula I f...
|
|
WO/2020/091522A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2020/053263A1 |
The present invention relates to thiocarbamate derivatives of Formula (I) which are useful as A2A adenosine receptor (A2AR) inhibitors (I). Especially, the present invention relates to a pharmaceutical composition comprising an A2A inhib...
|
|
WO/2019/155363A1 |
The present invention relates to benzo-imidazoindolizine derivatives, organic electroluminescence devices comprising said derivative, and the use of said derivative in organic electroluminescence devices.
|
|
WO/2019/144805A1 |
Provided are a substituted phenylethylamine compound as a μ opioid receptor agonist, a pharmaceutical composition comprising same, a preparation method therefor and the use of same for preventing and/or treating diseases associated with...
|
|
WO/2019/118973A1 |
The present invention relates to novel compounds of formula (I) or formula (Ia), pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for pre...
|
|
WO/2019/013249A1 |
A chromene compound showing a reduced matrix dependency and having at least one indenonaphthopyran structure which carries a group forming a spiro ring together with the carbon atom at the 13-position, wherein the indenonaphthopyran stru...
|
|
WO/2018/215318A1 |
The invention relates to heteroaromatic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention and to electronic devices containing same.
|
|
WO/2018/178338A1 |
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to...
|
|
WO/2018/019254A1 |
The present invention discloses a diphenyl ketone-based compound and an application thereof in an organo-electroluminescent device. The compound has the properties of limited intermolecular crystallization, limited clustering, and excell...
|
|
WO/2017/219917A1 |
Provided in the present invention is a new method for preparing a trabectedin, using safracin B as the starting material and through a series of reactions synthesizing trabectedin. The method easily obtains raw materials, has fewer synth...
|
|
WO/2017/213379A1 |
The present specification relates to an organic transistor comprising an organic semiconductor layer containing a compound and a gas sensor employing the same.
|
|
WO/2017/151947A1 |
The present disclosure relates to 4-azapodophylotoxins compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.
|
|
WO/2017/147161A1 |
Described herein are compounds, compositions, and methods of their use for the treatment of dermatological disorders or conditions.
|
|
WO/2017/134984A1 |
The invention provides a method for obtaining 2-methylspiro (1,3-oxathiolane-5,3') quinuclidine sulfate at a high isomer ratio (cis/trans) from 3-hydroxy-3-mercaptomethylquinuclidine without requiring fractionation of isomers or an isome...
|
|
WO/2017/121444A1 |
Compounds of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
|
|
WO/2017/020429A1 |
A nonaqueous electrolyte for a high-voltage lithium-ion battery and a lithium-ion battery. The electrolyte comprises a nonaqueous organic solvent, a lithium salt, and a double-nitrite compound selected from the structural formula 1, n be...
|
|
WO/2016/141563A1 |
The present invention aims to provide a novel alicyclic epoxide that is useful as a raw material of 2-hydroxyl-4-oxa-5-thia tricycle[4.2.1.03,7] nonane derivative. The alicyclic epoxide of the present invention is a compound represented ...
|
|
WO/2016/131521A1 |
The present invention relates to spirobifluorene derivatives of formula (I), the use thereof in electronic devices, and methods for producing said derivatives.
|
|
WO/2016/127924A1 |
The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acce...
|
|
WO/2016/106652A1 |
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds of Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is th...
|
|
WO/2016/106628A1 |
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, prov...
|
|
WO/2016/096686A1 |
The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.
|
|
WO/2016/022521A1 |
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver X receptor modulators, and which are useful in the treatment of diseases and disorders assoc...
|
|
WO/2015/147129A1 |
An organic transistor that has a semiconductor active layer containing a compound that can be represented by formula (1) and has a molecular weight of 3,000 or less exhibits high carrier mobility (X represents an oxygen, sulfur, selenium...
|
|
WO/2015/050989A3 |
The compounds and salts of the present invention inhibit kinases, especially the anaplastic lymphoma kinase (ALK) and the HGF receptor tyrosine kinase (RTK) c-Met, and are useful for treating or ameliorating abnormal cell proliferative d...
|
|
WO/2015/141765A1 |
The purpose of the present invention is to provide novel compounds useful in the production of salacinol and a method for producing these compounds, a method for producing salacinol, methods for protecting and deprotecting a diol grou...
|
|
WO/2015/123385A1 |
Described herein are modified sugar, iminosugar and azasugar compounds and methods of making same. One or more of these modified compounds contain sulfates, sulfites, sulfamates and/or sulfonamides. Also described are pharmaceutical comp...
|
|
WO/2015/039348A1 |
The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein n, X, Y, Z, R1, R2, and R3 are as defined herein. The present invention also relates to c...
|
|
WO/2014/206349A1 |
The present invention relates to an oxa-thia-bicyclo[3.2.1]octane derivative, a preparation method, and use of same, and particularly to an oxa-thia-bicyclo[3.2.1]octane derivative represented by the general formula (I) or a hydrate, a s...
|
|
WO/2014/188091A1 |
The invention relates to a multilayer superoleophobic and/or superhydrophobic material comprising: on the one hand, a first constituent that is a conductive substrate or a substrate that has previously been rendered conductive (1): • t...
|
|
WO/2014/129446A1 |
The purpose of the present invention is to provide a streptavidin mutant having reduced affinity for natural biotin, and to provide a biotin alterant having high affinity for the streptavidin mutant having low affinity for natural bio...
|
|
WO/2013/146356A1 |
A novel method for manufacturing an acrylic acid ester derivative capable of providing high resolution and having excellent lithography properties such as LWR when used as one unit of the polymer that is included in a photoresist composi...
|
|
WO/2013/143597A1 |
A compound of formula (I) and its use as an inhibitor of one or more histone demethylase enzymes.
|
|
WO/2013/146379A1 |
An acrylic acid ester derivative expressed by the general formula (1). In the formula, R1 represents a hydrogen atom or an alkyl group with 1 to 5 carbon atoms; and R2 represents a hydrogen atom, alkyl group with 1 to 5 carbon atoms, or ...
|
|
WO/2013/141143A1 |
Provided is a novel photochromic compound with favorable durability wherein the color during coloring is an intermediate color (exhibits double peak properties), color intensity is high, and color fading is rapid. For example, a chromene...
|
|
WO/2013/127267A1 |
Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.
|
|
WO/2013/041811A1 |
The present invention relates to organic compounds, usable as ligands in the preparation of lanthanide complexes or of certain water-soluble transition metals, a method for preparation thereof, and the use of said organic compounds as fl...
|
|
WO/2013/038374A1 |
The invention relates to a process for manufacturing the compound of formula 1-6 which is a synthetic intermediate commonly used in the preparation of antibiotic compounds, or for manufacturing salts of that compound. The invention furth...
|
|
WO/2013/013765A1 |
The invention relates to novel compounds based on thieno[3,2-b]thiophene- 2,5-dione and/or furo[3,2-b]furan-2,5-dione or their thioketone derivatives, methods for their preparation and intermediates used therein, mixtures and formulation...
|
|
WO/2013/010380A1 |
Provided are 6-5 membered fused pyridine ring compounds according to Formula (I) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is th...
|
|
WO/2012/176918A1 |
Specifically provided is a chromene compound represented by formula (1), which has a short fading half-life even at low temperatures in a common polymer solid matrix. (In formula (1), R1 represents a hydroxyl group or the like; each of R...
|
|
WO/2012/169605A1 |
In the present invention, a polymer compound containing a constitutional unit represented by formula (1), formula (2), formula (3) or formula (4) can be used to produce an organic thin film solar cell having a high open end voltage. (In ...
|
|
WO/2012/168241A1 |
The present invention provides substituted pyrazine compounds of the formula (I) or N-oxides or agriculturally suitable salts thereof, wherein the variables in the formula (I) are defined as in the description. Substituted pyrazines of f...
|
|
WO/2012/168397A1 |
The present invention provides substituted pyridine compounds of the formula (I) or N-oxides or agriculturally suitable salts thereof, wherein the variables in the formula (I) are defined as in the description. Substituted pyridines of f...
|
|
WO/2012/127472A1 |
The present invention describes processes for the synthesis of 2-(furan-2-yl)-7-[2-[4-[4-(2-methoxyethoxy)phenyl]piperazin-
l-yl] ethyl]-7H-pyrazolo[ 4,3-e ][1,2,4]- triazolo[1,5c] pyrimidin-5-amine (Preladenant) represented by the struc...
|
